ClinicalTrials.gov · NCT06889740 · Completed
Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced β-Nicotinamide Mononucleotide Calcium Salt) in Healthy Adult Participants
Registry record
NCT06889740 on ClinicalTrials.gov. The registry's last update to this record was 27 October 2026.
Verification record
5 checked · 0 company says · 0 reported · 0 not found · 0 not yet checked
- Title as registered Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced β-Nicotinamide Mononucleotide Calcium Salt) in Healthy Adult Participants Checked Source clinicaltrials.gov Brief title as registered. Checked
- Sponsor EffePharm LTD Checked Source clinicaltrials.gov Lead sponsor as registered. Checked
- Intervention NMNH-Ca; Placebo Checked Source clinicaltrials.gov Intervention names as registered. Checked
- Primary outcome as registered To assess NAD+ Values in blood | Assessment of Biological Age | Physical Performance walking test | Change in BMI | Quality (QoL) Questionnaire Checked Source clinicaltrials.gov Primary outcome measure(s) as registered. Checked
- Status Completed Checked Source clinicaltrials.gov Overall status as registered; registry last update 2026-10-27. Checked
Check history: NCT06889740 was last read on the registry on November 14, 2026. No earlier checks are recorded. How records are checked.
Corrections: none recorded for this trial. To ask for one, write to [email protected] with the registry number; every correction is checked against the registry record before the record changes.
As registered
- Sponsor: EffePharm LTD
- Phase: Not applicable
- Status: Completed
- Intervention: NMNH-Ca; Placebo
- Primary outcome: To assess NAD+ Values in blood | Assessment of Biological Age | Physical Performance walking test | Change in BMI | Quality (QoL) Questionnaire
- Countries: India
- Start: 8 July 2024
- Completion (actual): 25 January 2025
Results
No results were posted on the registry on the date checked. The Atlas does not summarize findings.
Related modality